620 filings
Page 5 of 31
424B5
gnz53r 6m3p17u6g
20 Mar 20
Prospectus supplement for primary offering
4:54pm
8-K
c88sugm7fvei 8fxm
20 Mar 20
Other Events
4:39pm
8-K
ro9bx8xvljq2k0y
3 Mar 20
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2019 Financial Results
7:22am
8-K
2422pwfob1ulpgsveo1o
26 Dec 19
Form of Securities Purchase Agreement
8:46am
424B5
kiyp74xh
23 Dec 19
Prospectus supplement for primary offering
7:39am
8-K
1qazmrj
9 Dec 19
Other Events
8:15am
8-K
4r5z8v58z8z
12 Nov 19
TG Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results
7:39am
8-K
4v0hlswhjv
28 Oct 19
Umbralisib monotherapy appeared to be well tolerated with a safety profile consistent with previous reports TG plans to present the data at a future medical conference and discuss the results with the FDA
7:59am
8-K
7me2t4g
12 Sep 19
Other Events
9:25am
S-3ASR
9qxal
5 Sep 19
Automatic shelf registration
4:17pm
RW
x3ef9t1q
5 Sep 19
Registration withdrawal request
4:00pm
8-K
yblrfx8qf15ly8heq
9 Aug 19
Results of Operations and Financial Condition
7:33am
8-K
o4o1ln immtwq1
13 Jun 19
Submission of Matters to a Vote of Security Holders
4:07pm
PX14A6G
tisc9ebp
31 May 19
Letter to shareholders
2:48pm
8-K
n1tppae2
10 May 19
TG Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results
7:01am